- Home
- SPFI vs AVBP Comparison
SPFI vs AVBP Comparison
Compare SPFI & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- AVBP
- Stock Information
- Founded
- SPFI 1941
- AVBP 2021
- Country
- SPFI United States
- AVBP United States
- Employees
- SPFI N/A
- AVBP N/A
- Industry
- SPFI Major Banks
- AVBP
- Sector
- SPFI Finance
- AVBP
- Exchange
- SPFI Nasdaq
- AVBP NYSE
- Market Cap
- SPFI 647.7M
- AVBP 617.4M
- IPO Year
- SPFI 2019
- AVBP 2024
- Fundamental
- Price
- SPFI $33.26
- AVBP $18.49
- Analyst Decision
- SPFI Buy
- AVBP Strong Buy
- Analyst Count
- SPFI 2
- AVBP 6
- Target Price
- SPFI $40.50
- AVBP $39.00
- AVG Volume (30 Days)
- SPFI 34.0K
- AVBP 178.0K
- Earning Date
- SPFI 04-24-2025
- AVBP 03-03-2025
- Dividend Yield
- SPFI 1.81%
- AVBP N/A
- EPS Growth
- SPFI N/A
- AVBP N/A
- EPS
- SPFI 2.92
- AVBP N/A
- Revenue
- SPFI $190,870,000.00
- AVBP N/A
- Revenue This Year
- SPFI $9.24
- AVBP $63.13
- Revenue Next Year
- SPFI $7.23
- AVBP N/A
- P/E Ratio
- SPFI $11.33
- AVBP N/A
- Revenue Growth
- SPFI N/A
- AVBP N/A
- 52 Week Low
- SPFI $24.05
- AVBP $14.35
- 52 Week High
- SPFI $40.91
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- SPFI 44.33
- AVBP 29.15
- Support Level
- SPFI $32.04
- AVBP $17.89
- Resistance Level
- SPFI $34.04
- AVBP $19.04
- Average True Range (ATR)
- SPFI 0.70
- AVBP 1.05
- MACD
- SPFI 0.12
- AVBP -0.02
- Stochastic Oscillator
- SPFI 46.23
- AVBP 13.34
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has two reportable segments: banking and insurance.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.